Gene transfer with herpes simplex vectors

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 5, 1999, Pages 622-632

  Lachmann, Robin H ^a,b   Efstathiou, Stacey ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b Division of Virology   (United Kingdom)

Author keywords

Gene therapy; Herpes simplex virus (HSV); HSV amplicon; Latency; Neuronal gene delivery; Viral vectors

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; REVIEW; SAFETY; TRANSGENE; VIRUS REPLICATION;

ANIMALS; DEFECTIVE VIRUSES; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, VIRAL; GENETIC VECTORS; HUMANS; NEOPLASMS; PROMOTER REGIONS (GENETICS); RECOMBINATION, GENETIC; SAFETY; SIMPLEXVIRUS; VIRULENCE; VIRUS REPLICATION;

EID: 0032692289     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Wagner EK, Bloom DC: Experimental Investigation of herpes simplex virus latency. Clin Microbiol Rev (1997) 10:419-443.
2. Stevens JG: Human herpesviruses: a consideration of the latent state. Microbiol Rev (1989) 53:318-332.
3. Efstathiou S, Minson AC, Field HJ, Anderson JR, Wildy P: Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans. J Virol (1986) 57:446-455.
4. Stevens JG, Wagner EK, Devi Rao GB, Cook ML, Feldman LT: RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science (1987) 235:1056-1059.
5. Glorioso JC, DeLuca NA, Fink DJ: Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol (1995) 49:675-710.
6. Lachmann RH, Efstathiou S: The use of herpes simplex virus-based vectors for gene delivery to the nervous system. Mol Med Today (1997) 3:404-411.
7. Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE, Martin GM, Jennings R, Ni Challanain D, Sobek I, Inglis SC, McLean CS: A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis (1997) 175:16-25.
8. Forrester A, Farrell H, Wilkinson G, Kaye J, Davis Poynter N, Minson T: Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted. J Virol (1992) 66:341-348.
9. Efstathiou S, Kemp S, Darby G, Minson AC: The role of herpes simplex virus type 1 thymidine kinase in pathogenesis. J Gen Virol (1989) 70:869-879.
10. Field HJ, Wildy P: The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (1978) 81:267-277.
11. Chrisp CE, Sunstrum JC, Averill DR, Levine M, Glorioso JC: Characterization of encephalitis in adult mice induced by intracerebral inoculation of herpes simplex virus type 1 (KOS) and comparison with mutants showing decreased virulence. Lab Invest (1989) 60:822-830.
12. Jacobson JG, Leib DA, Goldstein DJ, Bogard CL, Schaffer PA, Weller SK, Coen DM: A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology (1989) 173:276-283.
13. Cameron JM, McDougall I, Marsden HS, Preston VG, Ryan DM, Subak Sharpe JH: Ribonucleotide reductase encoded by herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol (1988) 69:2607-2612.
14. Valyi-Nagy T, Fareed MU, O'Keefe JS, Gesser RM, MacLean AR, Brown SM, Spivack JG, Fraser NW: The herpes simplex virus type 1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol (1994) 75:2059-2063.
15. Spivack JG, Fareed MU, Valyi Nagy T, Nash TC, O'Keefe JS, Gesser RM, McKie EA, MacLean AR, Fraser NW, Brown SM: Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model. J Gen Virol (1995) 76:321-332.
16. Bolovan CA, Sawtell CM, Thompson RL: ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J Virol (1994) 68:48-55.
17. Chou J, Kem ER, Whitley RJ, Roizman B: Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science (1990) 250:1262-1266.
18. Kucharczuk JC, Randanzzo B, Chang MJ, Amin KM, Elshami AA, Sterman DH, Rizk NP, Molnar-Kimber KL, Brown SM, Maclean AR, Litzky LA, Fraser NW, Albelda SM, Kaiser LR: Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res (1997) 57:466-471.
19. Randazzo BP, Kucharczuk JC, Litzky LA, Kaiser LR, Brown SM, MacLean A, Albelda SM, Fraser NW: Herpes simplex 1716 - an ICP 34.5 mutant - is severely replication restricted in human skin xenografts in vivo. Virology (1996) 223:392-395.
20. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM: Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant J Invest Dermatol (1997) 108:933-937.
21. Kesari S, Lasner TM, Balsara KR, Randazzo BP, Lee VM, Trojanowski JQ, Fraser NW: A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. J Gen Virol (1998) 79:525-536.
22. Markovitz NS, Baunoch D, Roizman B: The range and distribution of murine central nervous system cells infected with the γ34.5- mutant of HSV-1. J Virol (1997) 71:5560-5569.
23. Wagner EK, Guzowski JF, Singh J: Transcription of the herpes simplex virus genome during productive and latent infection. Prog Nucleic Acids Res Mol Biol (1995) 51:123-165.
24. Ecob-Prince MS, Preston CM, Rixon FJ, Hassan K, Kennedy PG: Neurons containing latency-associated transcripts are numerous and widespread in dorsal root ganglia following footpad inoculation of mice with herpes simplex virus type 1 mutant in 1814. J Gen Virol (1993) 74:985-994.
25. Ace CI, McKee TA, Ryan JM, Cameron JM, Preston CM: Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression. J Virol (1989) 63:2260-2269.
26. Preston CM, Mabbs R, Nicholl MJ: Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression. Virology (1997) 229:228-239.
27. Preston CM, Rinaldi A, Nicholl MJ: Herpes simplex virus type 1 immediate early gene expression is stimulated by inhibition of protein synthesis. J Gen Virol (1998) 79:117-124.
28. Chiocca EA, Choi BB, Cai WZ, DeLuca NA, Schaffer PA, DiFiglia M, Breakefield XO, Martuza RL: Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol (1990) 2:739-746.
29. Ho DY, Fink SL, Lawrence MS, Meier TJ, Saydam TC, Dash R, Sapolsky RM: Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects. J Neurosci Methods (1995) 57:205-215.
30. Johnson PA, Miyanohara A, Levine F, Cahill T, Friedmann T: Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol (1992) 66:2952-2965.
31. Wu N, Watkins SC, Schaffer PA, DeLuca NA: Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27 and ICP22. J Virol (1996) 70:6358-6369.
32. Samaniego LA, Neiderhiser L, DeLuca NA: Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol (1998) 72:3307-3320.
33. Samaniego LA, Wu N, DeLuca NA: The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol (1997) 71:4614-4625.
34. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M, Rouse RJ, Fink DJ, Glorioso JC: Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther (1998) 5:1593-1603.
35. Speck PG, Efstathiou S, Minson AC: in vivo complementation studies of a glycoprotein H-deleted herpes simplex virus-based vector. J Gen Virol (1996) 77:2563-2568.
36. Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, Pfaff DW: Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proc Natl Acad Sci USA (1994) 91:8979-8983.
37. During MJ, Naegele JR, O'Malley KL, Geller AI: Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science (1994) 266:1399-1403.
38. Dobson AT, Margolis TP, Sedarati F, Stevens JG, Feldman LT: A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons. Neuron (1990) 5:353-360.
39. Bloom DC, Maidment NT, Tan A, Dissette VB, Feldman LT, Stevens JG: Long-term expression of a reporter gene from latent herpes simplex virus in the rat hippocampus. Brain Res Mol Brain Res (1995) 31:48-60.
40. Wood MJ, Bymes AP, Pfaff DW, Rabkin SD, Charlton HM: Inflammatory effects of gene transfer into the CNS with defective HSV-1 vectors. Gene Ther (1994) 1:283-291.
41. Spaete RR, Frenkel N: The HSV amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell (1982) 30:295-304.
42. Ho DY: Amplicon-based herpes simplex virus vectors. Methods Cell Biol (1994) 43:191-210.
43. Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA, Breakefield XO: A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Hum Gene Ther (1996) 7:2003-2013.
44. Zhang X, O'Shea H, Entwisle O, Boursnell M, Efstathiou S, Inglis S: An efficient selection system for packaging herpes simplex virus amplicons. J Gen Virol (1998) 79:125-131.
45. Fraefel C, Song S, Lim F, Lang P, Yu L, Wang Y, Wild P, Geller AI: Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol (1996) 70:7190-7197.
46. Stavropoulos TA, Strathdee CA: An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol (1998) 72:7137-7143.
47. Starr PA, Lim F, Grant FD, Trask L, Lang P, Yu L, Geller AI: Long-term persistence of defective HSV-1 vectors in the rat brain is demonstrated by reactivation of vector gene expression. Gene Ther (1996) 3:615-623.
48. Palella TD, Hidaka Y, Silverman LJ, Levine M, Glorioso J, Kelley WN: Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector. Gene (1989) 80:137-144.
49. Fink DJ, Stemberg LR, Weber PC, Mata M, Goins WF, Glorioso JC: In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene Ther (1992) 3:11-19.
50. Andersen JK, Garber DA, Meaney CA, Breakefield XO: Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum Gene Ther (1992) 3:487-499.
51. Preston CM, Nicholl MJ: Repression of gene expression upon infection of cells with herpes simplex virus type 1 mutants impaired for immediate-early protein synthesis. J Virol (1997) 71:7807-7813.
52. Jamieson DR, Robinson LH, Daksis JI, Nicholl MJ, Preston CM: Quiescent viral genomes in human fibroblasts after infection with herpes simplex virus type 1 Vmw65 mutants. J Gen Virol (1995) 76:1417-1431.
53. Smith RL, Geller AI, Escudero KW, Wilcox CL: Long-term expression in sensory neurons in tissue culture from herpes simplex virus type 1 (HSV-1) promoters in an HSV-1-derived vector. J Virol (1995) 69:4593-4599.
54. Jacoby DR, Fraefel C, Breakefield XO: Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes. Gene Ther (1997) 4:1281-1283.
55. Fraefel C, Jacoby DR, Lage C, Hilderbrand, Chou JY, Alt FW, Breakefield XO, Majzoub JA: Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Mol Med (1997) 3:813-825.
56. Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakefield XO: HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther (1997) 8:359-370.
57. Goins WF, Lee KA, Cavalcoli JD, O'Malley ME, DeKosky ST, Fink DJ, Glorioso JC: Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. J Virol (1999) 73:519-532.
58. Lokensgard JR, Bloom DC, Dobson AT, Feldman LT: Long-term promoter activity during herpes simplex virus latency. J Virol (1994) 68:7148-7158.
59. Ecob-Prince MS, Hassan K, Denheen MT, Preston CM: Expression of beta-galactosidase in neurons of dorsal root ganglia which are latently infected with herpes simplex virus type 1. J Gen Virol (1995) 76:1527-1532.
60. Carpenter DE, Stevens JG: Long-term expression of a foreign gene from a unique position in the latent herpes simplex virus genome. Hum Gene Ther (1996) 7:1447-1454.
61. Jin BK, Belloni M, Conti B, Federoff HJ, Starr R, Son JH, Baker H, Job TH: Prolonged in vivo gene expression driven by a tyrosine hydroxylase promoter in a defective herpes simplex virus amplicon vector. Hum Gene Ther (1996) 7:2015-2024.
62. Song S, Wang Y, Bak SY, Lang P, Ullrey D. Neve RL, O'Malley KL, Geller AI: An HSV-1 vector containing the rat tyrosine hydroxylase promoter enhances both long-term and cell type-specific expression in the midbrain. J Neurochem (1997) 68:1792-1803.
63. Kesari S, Lee VM, Brown SM, Trojanowski JQ, Fraser NW: Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus-1. J Neurosci (1996) 16:5644-5653.
64. Deafly AM, Spivack JG, Lavi E, O'Boyle DR, Fraser NW: Latent herpes simplex virus type 1 transcripts in peripheral and central nervous system tissues of mice map to similar regions of the viral genome. J Virol (1988) 62:749-756.
65. Drummond CW, Eglin RP, Esiri MM: Herpes simplex virus encephalitis in a mouse model: PCR evidence for CNS latency following acute infection. J Neurol Sci (1994) 127:159-163.
66. Ramakrishnan R, Fink DJ, Jiang G, Desai P, Glorioso JC, Levine M: Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J Virol (1994) 68:1864-1873.
67. Dobson AT, Sederati F, Devi Rao G, Flanagan WM, Farrell MJ, Stevens JG, Wagner EK, Feldman LT: Identification of the latency-associated transcript promoter by expression of rabbit beta-globin mRNA in mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus. J Virol (1989) 63:3844-3851.
68. Margolis TP, Bloom DC, Dobson AT, Feldman LT, Stevens JG: Decreased reporter gene expression during latent infection with HSV LAT promoter constructs. Virology (1993) 197:585-592.
69. Wolfe JH, Deshmane SL, Fraser NW: Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MRS VII mice. Nature Genet (1992) 1:379-384.
70. Deshmane SL, Valyi Nagy T, Block T, Maggioncalda J, Wolfe JH, Dillner A, Fraser NW: An HSV-1 containing the rat beta-glucuronidase cDNA inserted within the LAT gene is less efficient than the parental strain at establishing a transcriptionally active state during latency in neurons. Gene Ther (1995) 2:209-217.
71. Lachmann RH, Brown C, Efstathiou S: A murine RNA polymerase 1 promoter inserted into the herpes simplex virus type 1 genome is functional during lytic, but not latent, infection. J Gen Virol (1996) 77:2575-2582.
72. Lachmann RH, Efstathiou S: Utilization of the herpes simplex virus type-1 latency-associated regulatory region to drive stable reporter gene expression in the nervous system. J Virol (1997) 71:3197-3207.
73. Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, Neuwelt EA: Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc Natl Acad Sci USA (1995) 92:9829-9833.
74. Muldoon LL, Nilaver G, Kroll RA, Pagel MA, Breakefield XO, Chiocca EA, Davidson BL, Weissleder R, Neuwelt EA: Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol (1995) 147:1840-1851.
75. Brooks AI, Halterman MW, Chadwick CA, Davidson BL, Haak Frendscho M, Radel C, Porter C, Federoff HJ: Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector. J Neurosci Methods (1998) 80:137-147.
76. Maidment NT, Tan AM, Bloom DC, Anton B, Feldman LT, Stevens JG: Expression of the lacZ reporter gene in the rat basal forebrain, hippocampus and nigrostriatal pathway using a nonreplicating herpes simplex vector. Exp Neurol (1996) 139:107-114.
77. Geller AI, Yu L, Wang Y, Fraefel C: Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Exp Neurol (1997) 144:98-102.
78. Federoff HJ, Geschwind MD, Geller AI, Kessler JA: Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia. Proc Natl Acad Sci USA (1992) 89:1636-1640.
79. Lawrence MS, Sun GH, Kunis DM, Saydam TC, Dash R, Ho DY, Sapolsky RM, Steinberg GK: Overexpression of the glucose transporter gene with a herpes simplex viral vector protects striatal neurons against stroke. J Cereb Blood Flow Metab (1996) 16:181-185.
80. Lawrence MS, McLaughlin JR, Sun GH, Ho DY, McIntosh L, Kunis DM, Sapolsky RM, Steinberg GK: Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J Cereb Blood Flow Metab (1997) 17:740-744.
81. Antonawich FJ, Federoff HJ, Davis JN: BCL-2 transduction, using a herpes simplex virus amplicon, protects hippocampal neurons from transient global ischemia. Exp Neurol (1999) 156:130-137.
82. Kim DH, McCormick F: Replicating viruses as selective cancer therapeutics. Mol Med Today (1996) 2:519-527.
83. Miyatake S, Martuza RL, Rabkin SD: Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther (1997) 4:222-228.
84. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, Whitley RJ: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther (1998) 5:121-130.
85. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, Whitley RJ: Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA (1995) 92:1411-1415.
86. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med (1995) 1:938-943.
87. McKie EA, MacLean AR, Lewis AD, Cruickshank G, Rampling R, Bamett SC, Kennedy PG, Brown SM: Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumors - evaluation of a potentially effective clinical therapy. Br J Cancer (1996) 74:745-752.
88. Kesari S, Randazzo BP, Valyi Nagy T, Huang QS, Brown SM, MacLean AR, Lee VM, Trojanowski JQ, Fraser NW: Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant Lab Invest (1995) 73:636-648.
89. McMenamin MM, Bymes AP, Pike FG, Charlton HM, Coffin RS, Latchman DS, Wood MJ: Potential and limitations of a gamma 34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS. Gene Ther (1998) 5:594-604.
90. Lasner TM, Kesari S, Brown SM, Lee VM, Fraser NW, Trojanowski JQ: Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol (1996) 55:1259-1269.
91. Lasner TM, Tal Singer R, Kesari S, Lee VM, Trojanowski JQ, Fraser NW: Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J Neurovirol (1998) 4:100-105.
92. 92. McMenamin MM, Bymes AP, Charlton HM, Coffin RS, Latchman DS, Wood MJ: A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. Neuroscience (1998) 83:1225-1237.
93. McKie EA, Brown SM, MacLean AR, Graham DI: Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy. Neuropathol Appl Neurobiol (1998) 24:367-372.
94. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena Esteves M, Aghi M, Bamett FH, Chiocca EA, Breakefield XO: Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 8:2057-2068.
95. Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA: Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther (1994) 1:323-331.
96. Carew JF, Federoff H, Halterman M, Kraus DH, Savage H, Sacks PG, Schantz SP, Shah JP, Fong Y: Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector. Am J Surg (1998) 176:404-408.
97. D'Angelica M, Karpoff H, Halterman M, Ellis J, Klimstra D, Edelstein D, Brownlee M, Federoff H, Fong Y: In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunol Immunother (1999) 47:265-271.
98. Dilloo D, Rill D, Entwistle C, Boursnell M, Zhong W, Holden W, Holladay M, Inglis S, Brenner M: A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood (1997) 89:119-127.
99. Wang M, Rancourt C, Navarro JG, Krisky D, Marconi P, Oligino T, Alvarez RD, Siegal GP, Glorioso JC, Curiel DT: High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type 1 vector. Gynecol Oncol (1998) 71:278-287.
100. Suzuki T, Piche A, Kasono K, Xiang J, Gomez Navarro J, Moriuchi S, Krisky DM, Oligino T, Glorioso JC, Curiel TJ, Curiel DT: Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy. Biochem Biophys Res Commun (1998) 252:686-690.
101. Wang S, Di S, Young WB, Jacobson C, Link CJ Jr. A novel herpesvirus amplicon system for in vivo gene delivery. Gene Ther (1997) 4:1132-1141.
102. Miyanohara A, Johnson PA, Elam RL, Dai Y, Witztum JL, Verma IM, Friedmann T: Direct gene transfer to the liver with herpes simplex virus type 1 vectors: transient production of physiologically relevant levels of circulating factor IX. New Biol (1992) 4:238-246.
103. Coffin RS, Howard MK, Gumming DV, Dollery CM, McEwan J, Yellon DM, Marber MS, MacLean AR, Brown SM, Latchman DS: Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors. Gene Ther (1996) 3:560-566.
104. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH: Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol (1997) 71:6641-6649.
105. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 272:263-267.
106. Xiao X, Li J, McCown TJ, Samulski RJ: Gene transfer by adeno-associated virus vectors into the CNS. Exp Neurol (1997) 144:113-124.